Alpha 2.0
Login Register
» Authors » Valter Torri

Valter Torri

Explore the profile of Valter Torri including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 214
Citations 8897
Followers 0
Related Specialties
Oncology
General Medicine
Pulmonary Medicine
Top 10 Co-Authors
Marina Chiara Garassino
Luca Porcu
Eliana Rulli
Irene Floriani
Giuseppe Lo Russo
Diego Signorelli
Gabriella Farina
Claudia Proto
Monica Ganzinelli
Filippo De Braud
Published In
J Clin Oncol
J Natl Cancer Inst
J Thorac Oncol
Lancet Oncol
ESMO Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer . 2025 Feb; 13(2). PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
2.
Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC"
Cameron R, Hines J, Torri V, Garassino M
J Thorac Oncol . 2024 Dec; 19(12):e80-e81. PMID: 39645303
No abstract available.
3.
A Response Letter by Cameron et al
Cameron R, Hines J, Torri V, Garassino M
J Thorac Oncol . 2024 Aug; 19(8):e26-e28. PMID: 39112011
No abstract available.
4.
How to Test for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405
Sartore-Bianchi A, Marsoni S, Amatu A, Torri V, Bonoldi E, Bardelli A, et al.
J Clin Oncol . 2024 Jul; 42(30):3631-3632. PMID: 39079079
No abstract available.
5.
Neoadjuvant or Perioperative Approach in Lung Cancer
Garassino M, Torri V
N Engl J Med . 2024 May; 390(19):1816-1818. PMID: 38749039
No abstract available.
6.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Hines J, Cameron R, Esposito A, Kim L, Porcu L, Nuccio A, et al.
J Thorac Oncol . 2024 Mar; 19(7):1108-1116. PMID: 38461929
Introduction: Controversy remains as to whether pathologic complete response (pCR) and major pathologic response (MPR) represent surrogate end points for event-free survival (EFS) and overall survival (OS) in neoadjuvant trials...
7.
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
Cerbone L, Delfanti S, Crivellari S, De Angelis A, Mazzeo L, Proto C, et al.
Tumori . 2024 Feb; 110(3):168-173. PMID: 38372045
Background: Pleural mesothelioma is a rare cancer with a dismal prognosis and few therapeutic options, especially in the pretreated setting. Immunotherapy with checkpoint inhibitors as single agents yielded interesting results...
8.
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies
Miglietta F, Dieci M, Giarratano T, Torri V, Giuliano M, Zustovich F, et al.
Eur J Cancer . 2023 Nov; 195:113399. PMID: 37950941
Background: The clinical value of tumor infiltrating lymphocytes (TILs) in hormone receptor-positive (HR+)/HER2- breast cancer (BC) may be unearthed by focusing on more biologically aggressive tumors. Here we deepen and...
9.
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment...
Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi F, Riva S, et al.
Eur J Cancer . 2023 Nov; 195:113404. PMID: 37948842
Background: In non-small cell lung cancer (NSCLC), the immune checkpoint inhibitors (ICI) revolution is rapidly moving from metastatic to early-stage, however, the impact of clinicopathological variables and optimal treatment sequencing...
10.
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors
Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, et al.
Lung Cancer . 2023 Nov; 186:107417. PMID: 37918061
Background: Bone-targeted agents (BTA), such as denosumab (DN) and zoledronic acid (ZA), have historically reduced the risk of skeletal related events in cancer patients with bone metastases (BM), with no...